SCHEMBL4680355

SCHEMBL4680355

CC(N)c1c(F)cccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
NFKB1 P19838 1/20 0.48
PNMT P11086 1/20 0.48
ALDH1A1 P00352 4/20 0.47
LMNA P02545 2/20 0.47
GLA P06280 1/20 0.47
TAAR1 Q96RJ0 2/20 0.42
GAA P10253 2/20 0.41
RIPK1 Q13546 1/20 0.38
CFD P00746 1/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HPGD P15428 2/20 0.36
ADRB2 P07550 1/20 0.35
TP53 P04637 1/20 0.35
HTT P42858 1/20 0.35
BACE1 P56817 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3775108 1.00 CYP1A2 (0.48) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL31521541 1.00 CYP1A2 (0.48) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL30818078 1.00 CYP1A2 (0.48) CYP1A2CYP3A4CYP2D6NFKB1PNMT
Hydrochloric Acid SCHEMBL20238704 0.98 ALDH1A1 (0.50) CYP1A2CYP3A4CYP2D6NFKB1PNMT
Hydrochloric Acid SCHEMBL29669028 0.98 ALDH1A1 (0.50) CYP1A2CYP3A4CYP2D6NFKB1PNMT
Hydrochloric Acid SCHEMBL20238705 0.98 ALDH1A1 (0.50) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL7350660 0.84 PNMT (0.58) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL16356139 0.84 HTR2A (0.39) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL16908267 0.84 HTR2A (0.39) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL1239996 0.84 HTR2A (0.39) CYP1A2CYP3A4CYP2D6NFKB1PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117529476-A Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments 亚飞络思制药公司 2024-02-06 CN disclosed
US-20230028114-A1 AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-01-26 US disclosed
EP-4031552-A1 AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES Takeda Pharmaceutical Company Limited (JP) 2022-07-27 EP disclosed
CN-114728975-A Azole-fused pyridazin-3 (2H) -one derivatives 武田药品工业株式会社 2022-07-08 CN disclosed
WO-2021055326-A1 AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 WO disclosed
US-9108955-B2 Heterocyclic inhibitors of necroptosis PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-08-18 US disclosed
US-20140128437-A1 HETEROCYCLIC INHIBITORS OF NECROPTOSIS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-05-08 US disclosed
US-8658689-B2 Heterocyclic inhibitors of necroptosis PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-02-25 US disclosed
US-8278344-B2 Heterocyclic inhibitors of necroptosis THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-10-02 US disclosed
US-20100317701-A1 HETEROCYCLIC INHIBITORS OF NECROPTOSIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-12-16 US disclosed
US-20090099242-A1 Heterocyclic inhibitors of necroptosis NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-04-16 US disclosed
EP-1931347-A2 PIPERAZINE DERIVATIVES M's Science Corporation (JP) 2008-06-18 EP disclosed
WO-2007021545-A2 PIPERAZINE DERIVATIVES M'S SCIENCE CORPORATION (JP) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230028114-A1 AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES GPR139, GPR119, GPR39 CYP1A2 979/4885CYP3A4 1477/4885CYP2D6 1394/4885
US-20100317701-A1 HETEROCYCLIC INHIBITORS OF NECROPTOSIS TNF, RIPK1, RIPK3 CYP1A2 4261/4885CYP3A4 3800/4885CYP2D6 3856/4885
US-20090099242-A1 Heterocyclic inhibitors of necroptosis TNF, RIPK1, RIPK3 CYP1A2 4261/4885CYP3A4 3800/4885CYP2D6 3856/4885
US-20140128437-A1 HETEROCYCLIC INHIBITORS OF NECROPTOSIS TNF, RIPK1, RIPK3 CYP1A2 4261/4885CYP3A4 3800/4885CYP2D6 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.